EGFR-targeting PLGA-PEG nanoparticles as a curcumin delivery system for breast cancer therapy
1Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, China.
Abstract:
Poor bioavailability and non-specificity of chemotherapeutic agents are major challenges in breast cancer treatment. Antibodies and small molecules that block cell signaling pathways have shown promise in the clinic, but their application is also limited by the high costs and treatment dosages required. Novel therapies that aim to rapidly and specifically target malignant cells with long-lasting impact in the tumor microenvironment may ultimately improve clinical outcome in cancer patients. Here, we demonstrate that epidermal growth factor receptor (EGFR)-targeting GE11 peptides conjugated with PEGylated polylactic-co-glycolic acid (PLGA) nanoparticles can be used to effectively deliver an anti-cancer agent, curcumin, into EGFR-expressing MCF-7 cells in vitro and in vivo. Treatment of breast cancer cells and tumor-bearing mice with these curcumin-loaded nanoparticles gave rise to reduced phosphoinositide 3-kinase signaling, decreased cancer cell viability, attenuated drug clearance from the circulation, and suppressed tumor burden compared with free curcumin or non-EGFR targeting nanoparticles. The targeted nanoscale drug delivery system we describe here may provide a new strategy for the design of targeted cancer therapy vectors. Our study provides evidence that the efficacy of pharmacologic anti-cancer agents can be enhanced through their delivery in the form of modified nanoparticles that effectively target specific malignant cell types.
Insights
Targeted nanoparticles carrying curcumin effectively deliver anti-cancer agents to breast cancer cells, reducing tumor growth and improving drug delivery. This novel approach enhances therapeutic efficacy for improved patient outcomes.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Chemotherapy for breast cancer faces challenges with poor bioavailability and lack of specificity.
- Current targeted therapies like antibodies and small molecules are limited by high costs and dosages.
Purpose of the Study:
- To develop and evaluate a targeted drug delivery system for breast cancer treatment.
- To investigate the efficacy of curcumin-loaded nanoparticles conjugated with GE11 peptides for targeting epidermal growth factor receptor (EGFR).
Main Methods:
- Conjugation of GE11 peptides with PEGylated polylactic-co-glycolic acid (PLGA) nanoparticles.
- Loading nanoparticles with the anti-cancer agent curcumin.
- In vitro and in vivo evaluation of targeted nanoparticle efficacy in EGFR-expressing breast cancer models (MCF-7 cells and tumor-bearing mice).
Main Results:
- Curcumin-loaded EGFR-targeted nanoparticles effectively delivered curcumin into cancer cells.
- Treatment reduced phosphoinositide 3-kinase signaling and decreased cancer cell viability.
- Targeted nanoparticles showed attenuated drug clearance and suppressed tumor burden compared to free curcumin.
Conclusions:
- EGFR-targeted nanoparticles offer a promising strategy for enhancing the efficacy of anti-cancer agents like curcumin.
- This targeted nanoscale drug delivery system represents a novel approach for designing effective cancer therapy vectors.
- Modified nanoparticles can significantly improve the therapeutic potential of existing pharmacologic agents in specific cancer types.
More Related Videos
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
09:09Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery
Published on: June 23, 2020
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers